Evolva announces that they have recently signed MTA’s to supply their high-quality Veri-te™ resveratrol for use in two upcoming clinical studies.
The first is a study led by Prof. Karen Brown (U. of Leicester, UK). 10 subjects on a high fat diet for 2 weeks. Veri-te™ resveratrol (1g/d). Will study the interaction between resveratrol and a high fat diet in terms of changes in metabolic profiles, with a particular focus on fatty acids and ketones that may be involved in cancer development. Completion of the study is expected by late 2018.
The second study is led by Prof. John Vissing and Nicoline Løkken (Rigshospitalet, Copenhagen, Denmark). 10 subjects with mitochondrial myopathy and 10 subjects with a fatty acid oxidation disorders in skeletal muscle in a cross-over study for 5 months (2x 8 weeks with a 4-week clearance period). Veri-te™ resveratrol (1g/d). The study will determine the effects of resveratrol supplementation on energy metabolism of muscle in patients with mitochondrial myopathies and skeletal muscle fatty acid oxidation disorders. Completion of the study is expected by mid-2019.